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Abstract 
The publication in April 2016 of the Assessment of the Validation Status of Health-Economic Decision Models (AdViSHE) checklist for 
decision models raises a number of issues that the health technology assessment literature has yet to address. The principal issue being 
the role of decision models in generating claims that are evaluable and replicable. Unfortunately, this is not addressed in this new 
checklist which is intended to address the perceived need for a tradeoff between confidence in a decision model and the need to allocate 
resources by developers and payers to validating the model. Irrespective of the degree of confidence a developer or payers may have 
in the sufficiency of the model in representing ‘reality’ unless the model has generated evaluable claims and evidence for those claims 
in target treating populations, the model fails the standards of normal science. Apart from the absence of a commitment in the AdViSHE 
checklist to the modeling of claims that are evaluable and replicable, the validation check list makes no allowance for a product pricing 
strategy that may commits a manufacturer to regular and substantial annual or semi-annual product price increases. Indeed, product 
pricing assumptions are conspicuous by their absence. The commentary argues that failure to accommodate anticipated pricing 
behavior renders lifetime cost-per-QALY models and the application of willingness-to-pay thresholds meaningless. 
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Introduction 
In April 2016, Vemer et al published details of the Assessment 
of the Validation Status of Health-Economic Decision Models 
(AdViSHE) tool 1. This tool is a checklist to support the 
validation of decision models. The objectives are to evaluate 
‘whether a model is a proper and sufficient representation of 
the system it is intended to represent’. For the authors, a 
‘proper’ model is one that ‘is in accordance with what is known 
about the system’ while ‘sufficient’ means that the results of 
the model can serve as a ‘solid basis’ for decision making’. 
Unlike previous attempts to set standards for model validity 
and quality assessment, the AdViSHE tool focuses on the 
potential trade-off between building confidence in the model 
and scare resources to support its validation. The tool presents 
a prioritized list of validation efforts with the objective of 
saving on scare resources yet improving the model’s validation 
status and acceptability for developers and payers. 
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The purpose of this commentary is to consider the AdViSHE 
tool kit and its recommendations for setting validation 
priorities from the perspective that the validation assessment 
is only meaningful if the model supports claims for product  
outcomes that are credible, evaluable and replicable, and 
where there is evidence for claims assessment 2. If the tool kit 
fails to support the assessment of claims, irrespective of what 
may be seen as the intrinsic merits or ‘sufficiency’ of the 
model, then the model fails the standards of normal science 3 
4 5 6. As such, it should be considered as ‘pseudoscience’, 
sharing the stage with intelligent design rather than natural 
selection. If this is the case then regardless of the belief in the 
‘sufficiency of the ‘proper’ model, where the results are 
necessarily entailed, it is difficult to see its role in providing a 
meaningful input to inform formulary decisions. Input that 
includes providing feedback for the claims made and 
supporting ongoing disease area and therapeutic class 
reviews. Irrespective, therefore, of the confidence the model 
builder may have in the model, this may not be shared by 
payers 7 8. More to the point, payers should be advised that 
models generating non-evaluable product should be rejected. 
 
The AdViSHE Toolkit 
The toolkif is the outcome of what is described as an 
exhaustive review process of modified Delphi rounds and a 
workshop at the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) 2014 Montreal meeting. The 
agreed final version of AdViSHE consists of 13 questions 
covering the validation of: (i) the conceptual model; (ii) input 
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data; (iii) the computerized model; and (iv) the behavior and 
accuracy of the model outcomes.   
 
The assessment checklist is in five parts. Part A addresses the 
issue of the validation of the conceptual model and comprises 
two questions. The first questions address the question of face 
validity through asking experts to judge the models 
appropriateness while the second question asks whether the 
model has been compared to other conceptual models to 
establish cross validity. Part B comprises two questions on 
input data validation to establish, first, an expert assessment 
of face validity for the appropriateness of the input data and, 
second, an evaluation of the fit of the model where the input 
parameters are based upon regression models. Part C 
comprises four questions on the validation of the 
computerized model. These cover: (i) an expert external 
review of the model; (ii) model testing for extreme values; (iii) 
a logic assessment of patient tracking through the model; and 
(iv) testing of sub-modules in the model. Part D considers, with 
four questions, the operational validity of the model. These 
are: (i) expert assessment of the face validity of the model 
outcomes; (ii) cross validation of the outcomes against those 
that address similar outcomes; (iii) validation against 
outcomes using alternative input data; and (iv) validation 
through comparing outcomes to empirical data. A final section, 
Part E, asks whether other validation techniques have been 
performed. 
 
The assessment checklist is seen as representing a 
compromise between what is feasible and what is necessary in 
decision modeling from developer and payer perspectives. It is 
seen as supplementing existing validation tools, with particular 
reference to the ISPOR-SMDM modeling standards, in asking 
which validation aspects were tested, how they were tested 
and where outcomes are reported 9 10.  In seeking to avoid 
duplicating validations while identifying unreported validation 
standards, the benefit of the AdViSHE tool is seen by its 
authors in its allowing model developers to build confidence in 
their model through commenting on validations already 
undertaken.  As such, it reduces overlap between validation of 
model developers and those of model users. The key 
assumption being, particularly from a payer perspective, that 
the criteria are relevant to their decision making.  
 
Credibility, Evaluation and Replication 
Although the AdViSHE framework addresses the issue of 
outcomes, there is no attempt to raise the issue of evaluable 
and replicable claims as a criterion for model validation. This is 
major oversight because it allows the model builder to fall back 
on claims that if the model is considered sufficient in its 
representation of ‘reality’ then, because the simulated 
outcomes are necessarily entailed, the model can ‘inform’ 
decision makers. Unfortunately, this position perpetuates the 
acceptance in health technology assessment of models that 
claim to meet validation standards yet fail to meet the 
standards for credible, evaluable and replicable claims. This is 
seen in the ISPOR-SDMS standards for modeling where 
predictive validation is seen as perhaps the most important 
test for model credibility as a validation standard yet one that 
is considered neither necessary nor sufficient in judging the 
merits of a model.  
 
It is far from clear what the term ‘outcomes’ is supposed to 
encompass in the AdViSHE checklist. While experts (Question 
D1) are asked to judge the appropriateness of the model 
outcomes, there is no discrimination between evaluable and 
non-evaluable claims. The same criticism applies to cross 
validation (Question D2) where the model outcomes are to be 
assessed against those of other models that address similar 
outcomes. There is no requirement that claims from 
competing models should be evaluated empirically. If there is 
no attempt to present evaluable claims, then the validation 
assessment is asked to contrast one set of non-evaluable 
claims against another. This seems to be an odd form of 
validation where a more appropriate assessment, if there are 
evaluable claims, is to contrast one model’s claims against 
those of another empirically. If this is not done than, 
irrespective of claims for the superiority of one model over 
another in its structure, assumptions, etc. the health care 
decision maker has no idea whether the claims are right or 
even if they are wrong. The same argument applies in respect 
of Question D3 where outcomes are validated against 
alternative input data. Finally, in validation against empirical 
data (Question D4) there is still confusion over what form a 
comparison should take. Information is requested on two 
aspects of possible empirical assessments: (i) comparisons 
based on summary statistics or patient level data sets; and (ii) 
differences between model outcomes and empirical data.  
These comparisons apparently involve (i) a comparison against 
the data sources on which the model is based (dependent 
validation) and (ii) a comparison against a data source that was 
not used to build the model (independent validation). While 
the latter comparison could be interpreted as an evaluation of 
claims in target treating populations, the context is far from 
clear. There is no hint that decision makers may prefer models 
that actually generate evaluable claims.  
 
Lifetime Cost-Per-QALY Models 
Although not mentioned, the AdViSHE toolkit is presumably 
relevant, not only to models that are designed to generate 
evaluable and replicable claims for outcomes in target 
populations, but also for models that are best described as 
‘imaginary worlds’. The failure to make this distinction is 
important because of the popularity of modeled imaginary 
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worlds in the health technology assessment literature 11 12 13 
14 15.  It is not clear from the AdViSHE tool whether there is a 
belief that, within each disease state, there exists an ‘ideal’ 
simulation: a model that, on the evidence available, can inform 
decision makers and justify formulary decisions across 
competing therapies. Otherwise, in the absence of any 
evaluable claims, we fall back on a (somewhat pointless) 
discussion of the relative merits of competing models, jostling 
for acceptance with competing manufacturers funding and 
publishing models that support their own product.   
 
Establishing reference case standards for modeled claims in 
single payer health system does not address the issue of claims 
credibility. Rather, acceptance of reference case frameworks, 
notably for long-term or lifetime modeling of chronic disease, 
reinforces the acceptance of modeled imaginary worlds as a 
valid input to formulary decision making. In reference case 
models the focus is on the model itself rather than any 
assessment of the claims generated by the model. In the case 
of the UK and the Netherlands, to give two examples, the 
reference case is the standard 16 17 18. As long as the model 
meets the reference case criteria and receives, in the case of 
NICE, the seal of approval from the external review group and 
the final NICE endorsement, the issue of claims evaluation is 
irrelevant 19. Indeed, as pointed out in previous reviews of the 
NICE evaluation framework, the reference case is not actually 
intended to generate evaluable claims. Rather, it is a pricing 
and resource allocation exercise. If, the final version of the 
model supports cost-per-QALY claims below a lifetime or long 
term cost-per-QALY willingness to pay threshold then the price 
proposed by a manufacturer is accepted. If not, negotiations 
to offer a lower price, discounts or some form of risk 
contracting ensue.  Manufacturers are on notice, therefore, 
that they need to submit a modeled reference case submission 
to support approval within the National Health Service. 
Whether they adjust their target price to meet a willingness-
to-pay threshold or opt to argue for a premium ‘above 
threshold’ price is their choice. The model, irrespective of how 
‘sufficient’ it is judged is immaterial as it makes no pretensions 
to generating evaluable claims.  
 
The situation in the US and in other non-single payer health 
systems is somewhat different. While the view that reference 
case and similar standards are nothing more than a pricing 
justification ‘rite of passage’ is echoed in the US in the reports 
generated by the Institute for Clinical and Economic Review 
(ICER), there appears to be little support for cost-per-QALY 
modeling and willingness-to-pay thresholds 20 21. The ICER 
approach mirrors that of NICE in the application of the 
reference case cost-per-QALY framework with willingness-to-
pay thresholds. Applying threshold values for cost-per-QALY 
gives a model framework to judge whether or not the price 
sought by manufacturers is deemed cost-effective. If the 
modeled cost-per-QALY falls below a threshold value it is 
judged cost-effective. Otherwise, the ICER may recommend a 
discounted price to bring it in line.  
 
A Foot in the Door 
Looking back over the past 20 years, it is not difficult to take 
the view that the effort put into developing standards and 
validation criteria for modeling and study design is seen, from 
the perspective of manufacturers who have underwritten 
much of this activity, as nothing more than an ‘academically 
respectable’ support for pricing and market share strategies. 
Unfortunately, the AdViSHE tool does nothing to dispel this 
belief as pricing assumptions are not considered as a validation 
element.  
 
Of course, as noted, in single payer systems, caps can be placed 
on pricing subsequent to market entry. This is not the case in 
the US. There is abundant evidence for what many observers 
see as a long term strategy by manufactures for regular price 
increases over the patent life of the product, supported by 
coupon discount policies to maintain market share.  Indeed, it 
is difficult (if not impossible) to find lifetime cost-per-QALY 
models that factor in long term pricing strategies as part of 
their long term modeled cost-per-QALY claims. Consider the 
case of multiple sclerosis drugs where a recent study by 
Hartnung et al, provides estimates of the trend in annual drug 
costs for nine of the disease modifying therapies (DMTs) from 
1993 to 2014 22.  Apart from the fact that DMT costs are two 
to three time bigger in the US than other countries, the 
principal finding is that DMT costs have accelerated well 
beyond inflation and substantially above rates for drugs 
observed in a similar biologic class. Annualized change in the 
cost of the DMTs ranged from 35.7% (glatiramer acetate) to 
7.9% for fingolimod. Four of the DMTs had annualized cost 
increases above 20% and four with annualized price increases 
between 13.0% and 16.8%. Natalizumab, for example, 
although being withdrawn briefly from the market between 
February 2005 and June 2006, increased in cost from $25,850 
in 2004 to $64,233 in 2013 or an annualized increase of 16.2%.  
 
If long-term pricing strategies are put to one side in favor of an 
assumption that the market entry WAC of a product will be 
maintained over its patent lifetime, then it is difficult to see 
what possible justification there is for a lifetime model to 
support claims for cost-effectiveness.  It is certainly neither 
‘sufficient’ nor ‘proper’. Attempts to maintain academic 
‘purity’ through advocating models that mimic the natural 
course of a disease, willingness-to-pay thresholds and the 
advocacy (at least in the US) for cost-per-QALY modeling seem 
misplaced.  The AdViSHE tool makes no mention of the 
advisability of incorporation models that build in unit price 
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increases as part of the model. Indeed, pricing is not 
mentioned as a discretionary variable that can be adjusted to 
support claims for comparative cost-effectiveness. 
 
Indeed, it would not be unreasonable to make the case that 
failure to include potential long-term pricing strategies in 
lifetime cost-per-QALY or cost per life year saved models, 
imparts a substantial element of bias in favor of claims for a 
manufacturer’s product. After all, if we consider the case of 
multiple sclerosis and consider a pricing strategy that increases 
an initial WAC by 10% per annum over a ten-year time frame 
the initial WAC will have increased by 135%. This does not 
include, of course, potential price increases for other direct 
medical costs.  Given this, it seems a little odd to apply a 
discount (the standard is 3%) to future costs based on the 
assumption. direct medical costs, to include, drug prices 
remain unchanged.  
 
Even if long-term models were modified to accommodate 
strategic pricing scenarios, the fact remains that such models 
are not intended to generate evaluable predictions. Until 
model developers accept the premise that health decision 
makers require claims that can be validated in a meaningful 
time frame, such models may be intended to inform but are 
unlikely to be accepted. In these circumstances it is difficult to 
see what role the AdViSHE tool can accomplish in bringing the 
two sides together. 
 
Conclusions 
The AdViSHE validation tool is probably best seen as a checklist 
to support pricing justification models. The fact that the focus 
is primarily on validating the core structure and assumptions 
of the model and not, as has been argued here and on a 
number of previous occasions, on developing testable 
hypotheses to support evaluation and replication of clinical 
and cost-effectiveness claims, makes it unlikely that formulary 
committees and other payers will pay it much attention. While 
the AdViSHE checklist is intended as a short-cut to assessing 
the validity of a model that is submitted to support outcome 
and pricing claims, the absence of criteria to support the 
credibility, evaluation and replication of claims is a major 
oversight 
 
From this perspective of claims evaluation, the willingness of 
manufacturers to underwrite lifetime cost-per-QALY models 
should be seen as simply an exercise to justify a pricing 
strategy. Formulary committees are asked to believe that the 
model justifies a price consistent with a target formulary 
position and, if possible, a premium price. The fact that a long-
term a strategy of regular price increases renders the initial 
modeling redundant is beside the point. The issue is one of 
supporting pricing negotiations and formulary acceptance. A 
position which is apparently accepted, but possibly not 
recognized, by academic groups and organizations such as the 
Academy of Managed Care Pharmacy (AMCP) and ISPOR, 
together with journal editors. Presumably, it could also be 
argued that, as long as the cost-per-QALY model is accepted 
for peer review and publication, the manufacturer has little if 
any interest in the intrinsic merits of the model or whether or 
not it adheres to the AdViSHE validation status checklist. The 
bottom line is achieving formulary acceptance at an entry price 
consistent with a manufacturer’s long-term pricing and market 
share strategy. 
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